Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex Dose-Finding for Rocuronium Reversal
NCT00535743Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2004
- Primary completion
- Jul 2004
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
A Phase 2 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Merck & Co.. Started Mar 2004; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT00535743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00535743.